FDA Eases Rules for Wearables and Health Software

Updated agency guidance gives wellness products, clinical decision software and AI tools more regulatory flexibility in 2026.

Updated on Nov. 19, 2026 in Health — General

FDA Eases Rules for Wearables and Health Software

Live Poll

Do you trust health apps and wearables to give you accurate information?

The U.S. Food and Drug Administration issued guidance updates in January clarifying when certain low-risk wellness products and software functions fall outside regulation. Its 2026 guidance gives wearables, clinical decision support software and AI tools more flexibility.

Why it matters

The updates clarify the boundary between general wellness products and regulated medical devices, which shapes how digital health companies design and market their tools. Manufacturers still must determine intended use and reassess classifications as FDA policy evolves.

The change is documented in FDA guidance updates issued in January 2026 rather than in measured outcome data, and the extraction does not provide quantitative figures. Specific products affected and enforcement practices remain unspecified.

The players

U.S. Food and Drug Administration

The U.S. Food and Drug Administration is the federal agency responsible for regulating medical devices, drugs and related products, including digital health technologies.

Squire Patton Boggs

Squire Patton Boggs is an international law firm whose attorneys advise companies on FDA regulatory compliance for medical and digital health products.

The details

Attorneys at Squire Patton Boggs outlined manufacturer obligations during a November 18 webinar. Manufacturers must assess intended use, document regulatory decisions and reassess classifications as products and FDA policies evolve.

Timeline

  1. January 2026: FDA issues guidance updates clarifying low-risk wellness products and software functions.

  2. 2026: FDA guidance gives wearables, clinical decision support software and AI tools more flexibility.

  3. November 18, 2026: Squire Patton Boggs holds a webinar on the FDA's digital health approach.

Regulatory Landscape

The 2026 guidance extends the FDA's longstanding general wellness policy, which separates low-risk wellness products from regulated medical devices, to newer wearables, decision support software and AI tools. It refines where that line falls as digital health products multiply.

Consumers using wearables and health apps may see wellness-labeled products that fall outside FDA medical-device regulation under the updated guidance. Companies building these tools must decide how their products are classified and document that decision.

The takeaway

Check whether a health app or wearable is marketed as a wellness product or a medical device, since that label determines how much regulatory oversight it has. Companies should document their intended use and revisit classifications as FDA policy changes.

Further reading

For broader context on medical and wellness regulation, see Health — General.

Source note: This article includes information reported by Insights.

Live Poll

Do you trust health apps and wearables to give you accurate information?